Jason O'Byrne - 22 Feb 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Reporting relationship: EVP & Chief Financial Officer
Issuer ticker: VIR
Reported as of: 22 Feb 2026
Net transaction value: -$15,569
SEC form: 4
Accepted by SEC: 24 Feb 2026, 19:12:25 UTC
Prior SEC filing: 18 Nov 2025
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Vanina de Verneuil, Attorney-In-Fact

Key filing fact

Jason O'Byrne filed Form 4 for Vir Biotechnology, Inc. (VIR) on 24 Feb 2026.

Key facts

This page summarizes Jason O'Byrne's Form 4 filing for Vir Biotechnology, Inc. (VIR).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2026, 19:12.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: -$15,569.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001871145 Primary reporting owner

O'Byrne Jason

Relationship: EVP & Chief Financial Officer
Address: C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO
Signature: /s/ Vanina de Verneuil, Attorney-In-Fact
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VIR transaction

Common Stock

Award

Transaction value: $0
Shares: +55,000
Change %: +49%
Price: $0.000000
Shares after: 166,338
Date: 22 Feb 2026
Ownership: Direct
Footnotes: F1, F2

VIR transaction

Common Stock

Sale

Transaction value: $15,569
Shares: -2,089
Change %: -1.3%
Price: $7.45
Shares after: 164,249
Date: 23 Feb 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VIR transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +110,000
Change %
Price: $0.000000
Shares after: 110,000
Date: 22 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 110,000
Exercise price: $7.56
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

Footnote F2

Includes 637 shares of common stock acquired by the Reporting Person on November 28, 2025, pursuant to an employee stock purchase program.

Footnote F3

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.

Footnote F4

25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.